Abilify Approval For Teens Is Bristol/Otsuka’s Latest Step In Franchise Expansion
Approval of the atypical antipsychotic for schizophrenia patients ages 13-17 comes more than two months after J&J’s Risperdal was cleared for adolescent schizophrenia.
Approval of the atypical antipsychotic for schizophrenia patients ages 13-17 comes more than two months after J&J’s Risperdal was cleared for adolescent schizophrenia.